Anavex Life Sciences (AVXL) Change in Receivables (2015 - 2019)
Anavex Life Sciences (AVXL) posted Change in Receivables of $17154.0 for Q2 2019, down 62.54% sequentially from $45788.0 in Q1 2019, and up 1412.7% YoY from $1134.0 in Q2 2018.
Anavex Life Sciences (AVXL) Change in Receivables (2015 - 2019) Analysis & Trends
Anavex Life Sciences has reported Change in Receivables for 5 years, with the latest figure at $17154.0 in Q2 2019.
- Quarterly Change in Receivables rose 1412.7% year-over-year to $17154.0 in Q2 2019, while the trailing twelve-month figure through Jun 2019 was $87169.0 (up 4309.03% YoY) and the FY2018 annual result came in at $30423.0, up 155.89% from the prior year.
- Change in Receivables eased to $17154.0 in Q2 2019 per AVXL's latest filing, from $45788.0 in the prior quarter.
- Over five years, Change in Receivables peaked at $45788.0 in Q1 2019 and troughed at -$37256.0 in Q2 2017.
- A 5-year average of $2109.2 and a median of $1134.0 in 2018 frame the typical range for Change in Receivables.
- The widest YoY moves for Change in Receivables: up 2121.02% in 2018, down 313.29% in 2018.
- Over 5 years, Change in Receivables stood at $15497.0 in 2015, then sank by 294.99% to -$30217.0 in 2016, then jumped by 92.15% to -$2371.0 in 2017, then slumped by 313.29% to -$9799.0 in 2018, then jumped by 275.06% to $17154.0 in 2019.
- According to Business Quant data, Change in Receivables over the past three periods registered $17154.0, $45788.0, and -$9799.0 for Q2 2019, Q1 2019, and Q4 2018 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 117.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -483,662.49 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 31.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 37.16 Mn |
| 10 | Anavex Life Sciences | 298.40 Mn | 166.65 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2019 | 17,154.00 |
| Jun 30, 2019 | 17,154.00 |
| Mar 31, 2019 | 45,788.00 |
| Mar 31, 2019 | 45,788.00 |
| Dec 31, 2018 | -9,799.00 |
| Dec 31, 2018 | -9,799.00 |
| Sep 30, 2018 | 34,026.00 |
| Sep 30, 2018 | 34,026.00 |
| Jun 30, 2018 | 1,134.00 |
| Jun 30, 2018 | 1,134.00 |
| Mar 31, 2018 | -2,366.00 |
| Mar 31, 2018 | -2,366.00 |
| Dec 31, 2017 | -2,371.00 |
| Dec 31, 2017 | -2,371.00 |
| Sep 30, 2017 | 1,532.00 |
| Sep 30, 2017 | 1,532.00 |
| Jun 30, 2017 | -37,256.00 |
| Jun 30, 2017 | -37,256.00 |
| Mar 31, 2017 | 11,506.00 |
| Mar 31, 2017 | 11,506.00 |